{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:39:53Z","timestamp":1787013593861,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Amenamevir is an oral once\u2010daily antiherpesvirus drug that can be administered without dose adjustment in patients with impaired renal function. There are currently no clinical data on immunocompromised patients with herpes zoster treated with amenamevir. Therefore, an exploratory study of the efficacy and safety of amenamevir against herpes zoster in patients with immunosuppression was conducted. Inclusion criteria included patients with acute herpes zoster receiving immunosuppressive drugs or those with malignant tumors or autoimmune diseases. Twenty\u2010four patients were included and received amenamevir (400\u2009mg once daily after meals) for up to 14\u2009days. The primary end point of overall improvement in skin symptoms 7\u2009days after treatment initiation (day 7) was 58.3% for \u201cmarkedly improved\u201d and 20.8% for \u201cimproved.\u201d The combined improvement rate was 79.2% (95% confidence interval, 57.8\u201392.9), and 20.8% of patients experienced \u201cworsened\u201d symptoms. The secondary end points of overall improvement in skin symptoms on day 14 and day 28 were 95.7% and 100%, respectively. The skin symptoms progressed during treatment, peaking on day 7, and then began to heal. By Kaplan\u2013Meier estimation, the median periods to complete crusting and healing were both day 14. There were five adverse events with a possible causal relationship to amenamevir (bacterial skin infection, anemia, hyponatremia, headache, and abnormal liver function) in one of the 24 patients. Although the bacterial skin infection was severe, all events in this patient were reported to be either recovered or recovering. These findings indicate that amenamevir can be effective and safe in immunocompromised patients with herpes zoster. However, as worsening can happen around day 7, it is necessary to carefully monitor such patients and switch to other therapies such as intravenous acyclovir if necessary.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Clinical trial identifier<\/jats:bold>\n                    : Japan Registry of Clinical Trials jRCTs031190208.\n                  <\/jats:p>","DOI":"10.1111\/1346-8138.17364","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T09:21:52Z","timestamp":1721812912000},"page":"1279-1289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An exploratory study of the efficacy and safety of amenamevir for the treatment of herpes zoster in patients receiving immunosuppressive drugs"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8568-4349","authenticated-orcid":false,"given":"Shinichi","family":"Imafuku","sequence":"first","affiliation":[{"name":"Department of Dermatology and Cosmetic Surgery Fukuoka University Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-9526","authenticated-orcid":false,"given":"Satoshi","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Federation of National Public Service Personnel Mutual Aid Associations Hamanomachi Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Urabe","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology National Hospital Organization Kyushu Medical Center  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kurume University Hospital  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hiroshima Red Cross Hospital and Atomic\u2010Bomb Survivors Hospital  Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daigo","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kawasaki Medical School Hospital  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-7033","authenticated-orcid":false,"given":"Takenobu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kawasaki Medical School General Medical Center  Okayama Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitake","family":"Ono","sequence":"additional","affiliation":[{"name":"Sasori Dermatology Clinic  Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeho","family":"Shirahama","sequence":"additional","affiliation":[{"name":"Department of Dermatology Seirei Mikatahara General Hospital  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Yasumoto","sequence":"additional","affiliation":[{"name":"Yasumoto Dermatology Clinic  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Medical Affairs, Maruho Co., Ltd  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp013211"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1086\/653605"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1302674"},{"key":"e_1_2_8_5_1","first-page":"2015","volume-title":"Fields virology","author":"Arvin AM","year":"2013"},{"key":"e_1_2_8_6_1","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP)","volume":"57","author":"Harpaz R","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23112"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0550-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq198"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0643-3"},{"key":"e_1_2_8_11_1","first-page":"53","article-title":"Assessment of anti\u2010VZV IgG antibodies in patients with facial palsy. Comparison between CF, FA and EIA","volume":"24","author":"Yamakawa K","year":"2004","journal-title":"Facial N Res Jpn"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0642-4"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1254\/fpj.153.35"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20936059"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-37"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-2-199507150-00002"},{"key":"e_1_2_8_17_1","first-page":"45","article-title":"Herpes zoster and subunit vaccine","volume":"71","author":"Imafuku S","year":"2021","journal-title":"Virus"},{"key":"e_1_2_8_18_1","first-page":"641","article-title":"Investigation of the safety and efficacy of amenamevir (Amenalief\u00ae tablet 200 mg) in patients with herpes zoster (interim report from a special drug use\u2010result survey)","volume":"37","author":"Imafuku S","year":"2020","journal-title":"J Jpn Org Clin Dermatol"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2022.12.008"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8581-21"},{"key":"e_1_2_8_21_1","article-title":"Varicella\u2010zoster meningitis and myelitis after herpes zoster dermatitis treatment with amenamevir: a case series and literature review","volume":"16","author":"Tada S","year":"2024","journal-title":"Cureus"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.cn-001531"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T03:22:51Z","timestamp":1727925771000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/1346-8138.17364"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17364","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"assertion":[{"value":"2024-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}